Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III AZD8205 versus physician's choice chemotherapy in B7-H4-selected endometrial cancer
NL-OMON60320Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of puxitatug samrotecan in endometrial cancer (EC) and carcinosarcoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)carcinosarcoma
Beyond the preview
Go deeper on NL-OMON60320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60320.